CD4 and type 2 diabetes mellitus: Of note, patients with type 2 diabetes showed an initial increment of CD4+TSCM, which may explain their comparable memory T cell responses and similar protection against severe COVID-19 infection as HCs following the second dose of BNT162b2 (25).